The chief medical officer at Ventyx Biosciences provided commentary on early clinical findings supporting NLRP3 inhibition with VTX3232 as a potential disease-modifying approach for Parkinson disease. [WATCH TIME: 4 minutes]
Mark Forman, MD, PhD
Advertisement
Articles by Mark Forman, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD
2
CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis
3
Reimagining Neuroscience Trials: Precision, Partnership, and Progress
4
Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID
5
